Alefacept is a genetically engineered immunosuppressive drug. It was sold under
the brand name Amevive in Canada, the United States, Israel, Switzerland and ...
Nov 16, 2011 ... Astellas Pharma U.S. Inc. (Astellas) has voluntarily discontinued the promotion,
manufacturing, distribution and sales of Amevive (alefacept), ...
AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that
consists ... AMEVIVE® for intramuscular injection contains 15 mg alefacept, 12.5
Alefacept is the first biological agent approved by the US Food and Drug
Administration (FDA) for the treatment of moderate to severe chronic plaque
intravenous injection contains 7.5 mg alefacept per 0.5 mL of reconstituted
solution. ... administration, the mean volume of distribution of alefacept was 94
Jun 11, 2015 ... Alefacept (Amevive) medication for adults with moderate to severe placuqe
psoriasis. Side effects, dosage, pregnancy safety information, and ...
Alefacept (amevive). Authoritative facts about the skin from DermNet New
Amevive (alefacept): For moderate to severe chronic plaque psoriasis.. New
approved drug details including side effects, uses and general information.
Medscape - Indication-specific dosing for Amevive (alefacept), frequency-based
adverse effects, comprehensive interactions, contraindications, pregnancy ...
Alefacept provides sustained clinical and immunological effects in new-onset
type 1 diabetes patients. Mark R. Rigby,<sup>1</sup> Kristina M. Harris,<sup>2</sup> Ashley Pinckney,<sup>3</sup> ...